has backed out of a Victorian government deal to set up a rapid antigen test manufacturing plant.
RATs were in scant supply at the time amid the nation’s first omicron wave, and the factory was expected to produce up to 50 million tests a year from October. “While we continue to see great potential for establishing a diagnostics capability in Victoria, at this time Lumos needs to focus on leveraging its existing assets rather than investing in new assets.”
On July 11, Lumos issued a statement revealing an application for approval of its lead test, FebriDx – a “key component of Lumos’ future commercial plans” – had been declined by the US Food and Drug Administration.
Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite: